首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Signal transduction and targeted therapy

缩写:

ISSN:2095-9907

e-ISSN:2059-3635

IF/分区:52.7/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引2606
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Sumei Chen,Haitao Zhu,Youssef Jounaidi Sumei Chen
Natural killer (NK) cells, initially identified for their rapid virus-infected and leukemia cell killing and tumor destruction, are pivotal in immunity. They exhibit multifaceted roles in cancer, viral infections, autoimmunity, pregnancy, w...
Ran An,Hao Yang,Cong Tang et al. Ran An et al.
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge and evade immunity, resulting in breakthrough infections in vaccinated populations. There is an urgent need for the development of vaccines with bro...
Guangcai Zhong,Xiaoyu Chang,Weilin Xie et al. Guangcai Zhong et al.
Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in disease management, providing a stark contrast to traditional therapeutic approaches like small molecule inhibitors that primarily focus on inhibiting pro...
Wei Li,Yongsheng Wang,Anwen Xiong et al. Wei Li et al.
Oncogenic RET alteration is an important, tissue-agnostic therapeutic target across diverse cancers. We conducted a first-in-human phase 1 study on SY-5007, a potent and selective RET inhibitor, in patients with RET-altered solid tumors. Pr...
Huan Zhang,Xian Xiao,Liping Wang et al. Huan Zhang et al.
UVB radiation induces oxidative stress, DNA damage, and inflammation, leading to skin wrinkling, compromised barrier function, and an increased risk of carcinogenesis. Addressing or preventing photoaging may offer a promising therapeutic av...
Hongtao Duan,Changjian Shao,Zhilin Luo et al. Hongtao Duan et al.
This open-label, single-arm, phase 2 trial evaluated the efficacy and safety of neoadjuvant sintilimab combined with anlotinib and chemotherapy, followed by adjuvant sintilimab, for resectable NSCLC. Forty-five patients received anlotinib (...